#Germany #Munich #Co-Diagnostics #Co-Dx PCR #ESCMID 2026

Co-Diagnostics Set to Shine at ESCMID 2026 in Munich

Co-Diagnostics, Inc., a key player in molecular diagnostics, is gearing up for its participation at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Global congress in 2026. Taking place from April 17 to 21 in Munich, Germany, this event promises to be a significant platform for networking and showcasing cutting-edge diagnostic technologies and innovations.

What to Expect at ESCMID 2026

Co-Diagnostics aims to engage with both global customers and distributors, solidifying its presence in the international market. The congress this year is anticipated to attract well over 16,000 attendees, comprising clinical microbiologists and infectious disease professionals, which underscores its relevance in advancing research and education in these critical fields.

Attendees will benefit from a robust programming lineup that bridges academic insights with industry developments. Such interactions are invaluable for exchanging knowledge and exploring advancements in scientific methods focused on infectious disease diagnostics and microbiology. Previous ESCMID events have seen participation from diverse geographical regions, reinforcing the event’s international stature.

The highlight of Co-Diagnostics’ showcase will be its suite of CE-IVD testing solutions specially designed for clinical laboratories. The company's innovative Co-Dx PCR platform is also set to take center stage. This new platform, which includes components such as PCR Home and PCR Pro, along with an accompanying mobile application, harnesses patented technology that enhances the accuracy and efficiency of molecular testing.

It is essential to note that the Co-Dx PCR platform is pending review by regulatory agencies, including the FDA, and is currently not available for commercial sale. This aspect does not deter interest, as the platform represents a potential game-changer for diagnostics, particularly for point-of-care testing at home.

Engaging with Global Professionals

Representatives from Co-Diagnostics are eager to meet with attendees at Booth #G55 to discuss its products, demonstrate the capabilities of its technologies, and foster new partnerships. Engaging face-to-face with scientists, healthcare professionals, and potential partners will enable Co-Diagnostics to expand its commercial relationships on a global scale.

In addition to networking, the company will gather crucial feedback from attendees to better refine and enhance its offerings. The technological advancements in diagnostics are crucial for improving patient outcomes and healthcare efficiency, and Co-Diagnostics is dedicated to leading the way in these innovations.

About Co-Diagnostics, Inc.

Co-Diagnostics, based in Salt Lake City, Utah, focuses on developing state-of-the-art diagnostics technologies. By utilizing its proprietary methods, the company designs tests aimed at detecting and analyzing nucleic acid molecules, which are fundamental in various medical applications, especially in infectious diseases. With a dedicated effort toward innovation and accuracy in diagnostics, Co-Diagnostics continually strives to address the pressing health challenges of today.

As the ESCMID Global 2026 approaches, the anticipation builds around what Co-Diagnostics will reveal and how their technology can reshape the future of molecular diagnostics. The upcoming congress serves not just as a platform for showcasing innovations but as a crucial assembly for the advancement of global health through collaborative learning and shared insights among the leaders in the field of clinical microbiology.